Yi Ming ang Ke rushed to Hong Kong shares: loss of 730million in the year Lilly and sunshine life insurance were shareholders

RedI network Lei Jianping 6 month 28 Reported Wednesday

Yiming Angke biomedical technology （ Shanghai ） limited company （ abbreviation ：“ Yiming Angke ”） The prospectus was submitted a few days ago , Ready to list in Hong Kong .

Loss during the year 7.33 Billion

Yiming Angke in 2015 year 6 Month in China （ Shanghai ） Free trade pilot zone Zhangjiang High Tech Park established , Focus on the development and research of anti-tumor immunotherapy products , It mainly includes new recombinant proteins 、 Bispecific antibodies 、 And TANK Cell therapy, etc , There are many new anti-tumor drugs in clinical research stage .

The common feature of these products is to exert the anti-tumor effect by stimulating and mobilizing the patient's own immune system , And ultimately inhibit the continued growth of tumor cells , Reverse a series of malignant symptoms caused by this , So that the patient can gradually return to a healthy body state .

The prospectus shows , Oncology 2020 year 、2021 The annual revenue is 119 Ten thousand yuan 、507 Ten thousand yuan ; Losses during the year are 6.6 One hundred million yuan 、7.33 One hundred million yuan .

Oncology 2020 year 、2021 The annual adjusted net losses were 8386 Ten thousand yuan 、1.83 One hundred million yuan .

By 2021 year 12 month 31 Japan , The cash set cash equivalents held by Anke biological are 6.68 One hundred million yuan .

Appoint several senior executives

The executive directors of Yiming Angke are tianwenzhi 、 Li Song 、 Ms. song Ziyi ; The non-executive directors are Dr. xucong 、 Yuzhihua 、 Yuxiaoyong ; The independent non-executive directors are Dr. zhuzhenping 、Kendall A. Smith Doctor 、 Yangzhida .

2021 year 7 month 26 Japan , Yiming Anke announced , Appoint Ms. songziyi as the chief financial officer of the company (CFO), Report to Dr. tianwenzhi, chairman and general manager of Yiming Angke . Ms. song Ziyi led and was responsible for the financing and listing of Yiming Angke 、 financial transactions 、 Financial strategy, etc .

Ms. song Ziyi holds a bachelor's degree in economics and mathematics from the University of Chicago ,15 At least years of investment management experience in international investment banking and medical field , Have a wealth of IPO、 financing 、 Experience in capital markets such as mergers and acquisitions , While in investment banking , Responsible for completing 50 Multiple capital market transactions .

2022 year 3 month 30 Japan , Yiming Anke announced , Xuwencheng was appointed as vice president of clinical operation of the company .

2022 year 4 month 1 Japan , Yiming Anke announced , Dr. ganxiaodong was appointed as the senior vice president of the company , Mainly responsible for the company's clinical trials in the United States .

Lilly and sunshine life are shareholders

2020 year 10 month 10 Japan , Yiming Anke announced the completion of 2500 Thousands of dollars B Round of funding . This financing is provided by Lilly Asia Fund （LAV） Lead investment , Jifeng capital （LYFECapital） To vote for ;A The investor will continue to make additional investment in the converted assets .

2021 year 3 month 24 Japan , Yiming Anke announced the completion of 8900 Thousands of dollars B+ Round of funding . The financing is provided by Dawan District common home development fund （ Dawan district fund ） And Lilly Asia Fund （LAV） Jointly lead the investment , Shanghai Science and technology innovation fund Co., Ltd ,Pre-A Round investor Zhang Ke Lingyi and B Round investor LYFECapital（ Jifeng ） Continue to make additional investment . Lilly Asia Fund （LAV） and LYFECapital（ Jifeng ） Continuous additional investment .

2021 year 12 month , Yiming Anke announced the completion of nearly 1 Billion dollars C Round of funding . This financing is provided by sunshine insurance 、 Rehabilitation and Growth Fund 、 Guokejiahe 、 Rongchang venture capital 、 Fang zhenghesheng 、 CCB trust 、 Create the East 、 New investors such as Kuanyu capital , And Lilly Asia Fund （LAV）、 The original shareholders, such as the assets, shall jointly complete .

IPO front , Founder of Yiming Angke 、 Chairman of the board of directors 、CEO、 Dr. tianwenzhi, chief scientific officer and executive director, has 33.29% Right to vote ： He directly holds 70,182,990 shares ; And employee stock ownership platform （ Jiaxing Changxian 、 Jiaxing Changyu and Halo InvestmentII） Held in total 48,356,955 shares .

Jiaxing Changxian and Jiaxing Changyu are limited partnership enterprises registered and established in China , Their respective executive partners are controlled by Tian Wenzhi .

Lilly holdings is 12.25%, Zhangke Lingyi venture capital holds shares of 11.89%, Longpan capital holds shares of 5.41%,Milestone The shareholding is 4.65%, The shareholding of ZhouLing capital is 4.5%,GBA Investment The shareholding is 3.89%, Zhang Jiangke investment holds shares of 3.05%, LANXESS investment holds 2.71%;

Yarrow investment holds 2.2%, Ruiji phase III holds 1.95%, Sunshine life holds 1.88%, Ming Lang capital holds shares of 1.48%, Jiaxing Qiyue holds shares of 1.46%, Kechuang capital's shareholding is 1.2%.

———————————————

Lei Di was founded by Lei Jianping, a senior media person , If reproduced, please indicate the source .